Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOLANTHE olaparib plus bevacizumab frontline maintenance trial in HRD-positive ovarian tumors
2022-502242-27-00Phase 4Authorised
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of olaparib and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Progression-free survival rate at 24 months. Planned start Jun 2023; status: authorised.
02
Drugs
olaparibbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2022-502242-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502242-27-00.